Metabolic Imaging in Cardio-oncology

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.

Original languageEnglish (US)
Pages (from-to)357-366
Number of pages10
JournalJournal of cardiovascular translational research
Issue number3
StatePublished - Jun 1 2020


  • Cancer
  • Cardio-toxicity
  • Chemotherapy
  • Metabolism

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmaceutical Science
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)


Dive into the research topics of 'Metabolic Imaging in Cardio-oncology'. Together they form a unique fingerprint.

Cite this